Company Filing History:
1 out of 60 
1 out of 4 
1 out of 56 Years Active: 2022
Title: Masatomo Iwao: Innovator in Cancer Treatment
Introduction
Masatomo Iwao is a notable inventor based in Nagasaki, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and development of targeted therapies. His work primarily focuses on addressing challenges in treating non-small cell lung cancer.
Latest Patents
Masatomo Iwao holds a patent for a fourth-generation EGFR tyrosine kinase inhibitor. This compound exhibits specific inhibitory activity against the C797S resistant mutant EGFR, particularly the C797S tertiary-resistant mutant EGFR. It is designed to be an effective agent for preventing and treating non-small cell lung cancer associated with resistant mutant EGFR.
Career Highlights
Throughout his career, Masatomo Iwao has been affiliated with prestigious institutions such as Nagasaki University and Iwate Medical University. His research has contributed to advancements in targeted cancer therapies, showcasing his commitment to improving patient outcomes.
Collaborations
Masatomo Iwao has collaborated with esteemed colleagues, including Tsutomu Fukuda and Fumito Ishibashi. These partnerships have enhanced his research efforts and expanded the impact of his work in the medical field.
Conclusion
Masatomo Iwao's innovative contributions to cancer treatment through his patent for a fourth-generation EGFR tyrosine kinase inhibitor highlight his dedication to advancing medical science. His work continues to inspire future research in the fight against cancer.